The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...